A 38-year-old man with HIV-1 infection on efavirenz-based ART for 2 years presents with virological failure (VL 45,000 copies/mL). Genotyping shows K103N mutation. Which feature best distinguishes his options between switching to a PI-based regimen versus a dolutegravir-based regimen?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.